Depressive symptoms and exposure to efavirenz in West African HIV-infected adults

HIV Clinical Trials

Volumn 9, Issue 6, 2008, Pages 445-447

  Marcellin, Fabienne ^a,b,c   Moh, Raoul ^d,e   Carrieri, Maria Patrizia ^a,b,c   Danel, Christine ^d,e   Protopopescu, Camelia ^a,b,c   Gabillard, Delphine ^d,e   Spire, Bruno ^a,b,c   Anglaret, Xavier ^d,e  

^a AIX MARSEILLE UNIV   (France)

^b AIX MARSEILLE UNIVERSITY   (France)

^c OBSERVATOIRE RÉGIONAL DE LA SANTÉ PROVENCE ALPES CÔTE D AZUR   (France)

^d Programme PAC CI   (Côte d’Ivoire)

^e U897 ^*  (France)

Author keywords

[No Author keywords available]

Indexed keywords

EFAVIRENZ; LAMIVUDINE; PROTEINASE INHIBITOR; ZIDOVUDINE;

ADULT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COTE D'IVOIRE; DEPRESSION; DOSAGE SCHEDULE COMPARISON; DRUG DOSE REGIMEN; DRUG EXPOSURE; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LETTER; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADULT; AFRICA, WESTERN; ANTI-HIV AGENTS; BENZOXAZINES; DEPRESSION; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; INTERVIEWS AS TOPIC; LAMIVUDINE; MALE; REVERSE TRANSCRIPTASE INHIBITORS; TREATMENT OUTCOME; ZIDOVUDINE;

EID: 62649136124     PISSN: 15284336     EISSN: None     Source Type: Journal    
DOI: 10.1310/hct0906-445     Document Type: Letter

References (11)

1. World Health Organization. Antiretroviral Treatment for HIV Infection in Adults and Adolescents: Towards Universal Access. Recommendations for a Public Health Approach. 2006 Revision. Geneva: WHO; 2006.
2. World Health Organization. Towards Universal Access - Scaling up Priority HIV/AIDS Interventions in the Health Sector. Geneva: WHO; 2008.
3. Renaud-Thery F, Nguimfack BD, Vitoria M, et al. Use of antiretroviral therapy in resource-limited countries in 2006: Distribution and uptake of first- and second-line regimens. AIDS. 2007;21(Suppl 4):S89-95.
4. Arendt G, de Nocker D, von Giesen HJ, Nolting T. Neuropsychiatric side effects of efavirenz therapy. Expert Opin Drug Saf. 2007;6(2):147-154.
5. Spire B, Carrieri P, Garzot MA, L'Henaff M, Obadia Y. Factors associated with efavirenz discontinuation in a large community-based sample of patients: AIDS Care. 2004; 16(5):558-564.
6. Peyriere H, Mauboussin JM, Rouanet I, Fabre J, Reynes J, Hillaire-Buys D. Management of sudden psychiatric disorders related to efavirenz. AIDS. 2001;15(10):1323-1324.
7. Journot V, Chene G, De Castro N, et al. Use of efavirenz is not associated with a higher risk of depressive disorders: A substudy of the randomized clinical trial ALIZE-ANRS 099. Clin Infect Dis. 2006;42(12):1790-1799.
8. Poupard M, Ngom Gueye NF, Thiam D, et al. Quality of life and depression among HIV-infected patients receiving efavirenz- or protease inhibitor-based therapy in Senegal. HIV Med. 2007;8(2):92-95.
9. Danel C, Moh R, Minga A, et al. CD4-guided structured antiretroviral treatment interruption strategy in HIV-infected adults in west Africa (Trivacan ANRS 1269 trial): A randomised trial. Lancet. 2006;367(9527):1981-1989.
10. Furher R, Rouillon F. La version française de l'echelle CES-D. Description and translation of the auto-evaluation [in French]. Psychiatrie et Psychobiologie 1989;4:163-166.
11. Vanable PA, Carey MP, Blair DC, Littlewood RA. Impact of HIV-related stigma on health behaviors and psychological adjustment among HIV-positive men and women. AIDS Behav. 2006;10(5):473-482.